Leronlimab Evidence: Trial Results and Peer-Reviewed Publications

Hipa.ai Research · Source: PubMed & ClinicalTrials.gov / AACT · Last updated:

The clinical evidence base for Leronlimab comprises 5 peer-reviewed publications across 5 journals, 0 pivotal-trial primary-outcome rows reported to ClinicalTrials.gov, spanning indications including COVID-19, and Non-alcoholic Fatty Liver Disease. Most recent publication: A Randomized Placebo-Controlled Trial of Leronlimab in Mild-To-Moderate COVID-19., Clin Ther, 2024.

Top peer-reviewed publications

Curated set of pivotal-trial result papers and recent publications in high-tier journals.

  1. A Randomized Placebo-Controlled Trial of Leronlimab in Mild-To-Moderate COVID-19.
    Seethamraju H, Yang OO, Loftus R, et al. · Clin Ther · 2024
    PubMed: PMID 39353749 · NCT04343651 · COVID-19
  2. Reduced Cell Surface Levels of C-C Chemokine Receptor 5 and Immunosuppression in Long Coronavirus Disease 2019 Syndrome.
    Gaylis NB, Ritter A, Kelly SA, et al. · Clin Infect Dis · 2022
    PubMed: PMID 35452519 · NCT04678830 · COVID-19
  3. CCR5 Receptor Occupancy Analysis Reveals Increased Peripheral Blood CCR5+CD4+ T Cells Following Treatment With the Anti-CCR5 Antibody Leronlimab.
    Chang XL, Wu HL, Webb GM, et al. · Front Immunol · 2022
    PubMed: PMID 34868084 · NCT04678830 · COVID-19
  4. Using NEWS2: an essential component of reliable clinical assessment.
    Welch J, Dean J, Hartin J, et al. · Clin Med (Lond) · 2022
    PubMed: PMID 36427875 · NCT04347239 · COVID-19
  5. Diagnostic performance of FibroTest, SteatoTest and ActiTest in patients with NAFLD using the SAF score as histological reference.
    Munteanu M, Tiniakos D, Anstee Q, et al. · Aliment Pharmacol Ther · 2017
    PubMed: PMID 27549244 · NCT04521114 (NASH) · Non-alcoholic Fatty Liver Disease

Publications by year

2017–2024: 5 publications.

2017
1
2022
3
2024
1

Publications by indication

COVID-19 (4)

  • A Randomized Placebo-Controlled Trial of Leronlimab in Mild-To-Moderate COVID-19.
    Clin Ther · 2024 · PMID 39353749 · NCT04343651
  • Reduced Cell Surface Levels of C-C Chemokine Receptor 5 and Immunosuppression in Long Coronavirus Disease 2019 Syndrome.
    Clin Infect Dis · 2022 · PMID 35452519 · NCT04678830
  • CCR5 Receptor Occupancy Analysis Reveals Increased Peripheral Blood CCR5+CD4+ T Cells Following Treatment With the Anti-CCR5 Antibody Leronlimab.
    Front Immunol · 2022 · PMID 34868084 · NCT04678830
  • Using NEWS2: an essential component of reliable clinical assessment.
    Clin Med (Lond) · 2022 · PMID 36427875 · NCT04347239

Non-alcoholic Fatty Liver Disease (1)

  • Diagnostic performance of FibroTest, SteatoTest and ActiTest in patients with NAFLD using the SAF score as histological reference.
    Aliment Pharmacol Ther · 2017 · PMID 27549244 · NCT04521114

Publications by journal

  • Clin Ther1 paper
  • Clin Infect Dis1 paper
  • Front Immunol1 paper
  • Clin Med (Lond)1 paper
  • Aliment Pharmacol Ther1 paper

All Leronlimab publications (5)

2024 (1 paper)

  1. A Randomized Placebo-Controlled Trial of Leronlimab in Mild-To-Moderate COVID-19.
    Seethamraju H, Yang OO, Loftus R, et al. · Clin Ther · 2024 · Derived
    PubMed: PMID 39353749 · NCT04343651 · COVID-19

2022 (3 papers)

  1. Reduced Cell Surface Levels of C-C Chemokine Receptor 5 and Immunosuppression in Long Coronavirus Disease 2019 Syndrome.
    Gaylis NB, Ritter A, Kelly SA, et al. · Clin Infect Dis · 2022 · Derived
    PubMed: PMID 35452519 · NCT04678830 · COVID-19
  2. CCR5 Receptor Occupancy Analysis Reveals Increased Peripheral Blood CCR5+CD4+ T Cells Following Treatment With the Anti-CCR5 Antibody Leronlimab.
    Chang XL, Wu HL, Webb GM, et al. · Front Immunol · 2022 · Derived
    PubMed: PMID 34868084 · NCT04678830 · COVID-19
  3. Using NEWS2: an essential component of reliable clinical assessment.
    Welch J, Dean J, Hartin J, et al. · Clin Med (Lond) · 2022 · Background
    PubMed: PMID 36427875 · NCT04347239 · COVID-19

2017 (1 paper)

  1. Diagnostic performance of FibroTest, SteatoTest and ActiTest in patients with NAFLD using the SAF score as histological reference.
    Munteanu M, Tiniakos D, Anstee Q, et al. · Aliment Pharmacol Ther · 2017 · Background
    PubMed: PMID 27549244 · NCT04521114 (NASH) · Non-alcoholic Fatty Liver Disease

Sources and methodology

  • Publications: ctgov.study_references (PubMed PMIDs auto-attached by ClinicalTrials.gov to each trial), reference types RESULT, DERIVED, and BACKGROUND.
  • Per-arm outcome values: ctgov.outcome_measurements joined to ctgov.design_outcomes where outcome_type = 'PRIMARY', restricted to phase PHASE3 and PHASE2/PHASE3.
  • Publication metadata (title, journal, year, authors): PubMed E-utilities efetch.fcgi
  • Data freshness: Tue, 26 May 2026 18:07:38 GMT.
This page summarizes published evidence for general reference and does not constitute medical advice. For clinical decisions, consult the linked primary publications and your healthcare provider. Data sourced from PubMed and the ClinicalTrials.gov / AACT database maintained by the Clinical Trials Transformation Initiative (CTTI).